Literature DB >> 36030403

A roadmap for clinical trial design in marginal zone lymphoma.

Juan Pablo Alderuccio1, Thomas Habermann2, Russ Kuker3, Craig H Moskowitz1, Andrew D Zelenetz4,5, Izidore S Lossos1.   

Abstract

Marginal zone lymphoma (MZL) is commonly underrepresented in clinical trials collectively studying mostly nodal indolent lymphomas.In this manuscript we propose new inclusion and response criteria defined by MZL subtype and disease location for those with extranodal MZL. Progression of disease within 24 months is associated with poor outcomes in MZL and future studies should assess the efficacy of novel agents in this population.
© 2022 Wiley Periodicals LLC.

Entities:  

Mesh：

Year:  2022        PMID： 36030403      PMCID： PMC9561038          DOI： 10.1002/ajh.26706

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   13.265


  40 in total

1.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Authors:  Nathan H Fowler; R Eric Davis; Seema Rawal; Loretta Nastoupil; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle A Fanale; Luis E Fayad; Jason R Westin; Jatin Shah; Robert Z Orlowski; Michael Wang; Francesco Turturro; Yasuhiro Oki; Linda C Claret; Lei Feng; Veerabhadran Baladandayuthapani; Tariq Muzzafar; Kenneth Y Tsai; Felipe Samaniego; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

2.  Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Authors:  Luciano Cascione; Andrea Rinaldi; Alessio Bruscaggin; Chiara Tarantelli; Alberto J Arribas; Ivo Kwee; Lorenza Pecciarini; Afua A Mensah; Valeria Spina; Elaine Y L Chung; Lodovico Terzi di Bergamo; Stephan Dirnhofer; Alexandar Tzankov; Roberto N Miranda; Ken H Young; Alexandra Traverse-Glehen; Gianluca Gaidano; Steven H Swerdlow; Randy Gascoyne; Raul Rabadan; Maurilio Ponzoni; Govind Bhagat; Davide Rossi; Emanuele Zucca; Francesco Bertoni
Journal:  Haematologica       Date:  2019-04-24       Impact factor: 9.941

3.  Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.

Authors:  Stefano Luminari; Michele Merli; Sara Rattotti; Vittoria Tarantino; Luigi Marcheselli; Federica Cavallo; Marzia Varettoni; Benedetta Bianchi; Francesco Merli; Alessandra Tedeschi; Giuseppina Cabras; Francesca Re; Carlo Visco; Marcia Torresan Delamain; Emanuele Cencini; Michele Spina; Simone Ferrero; Angela Ferrari; Marina Deodato; Donato Mannina; Ombretta Annibali; Angela Rago; Lorella Orsucci; Irene Defrancesco; Marco Frigeni; Marina Cesaretti; Luca Arcaini
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

4.  First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad Kahl; Peter Wood; Tim Hawkins; David MacDonald; David Simpson; Kathryn Kolibaba; Samar Issa; Julie Chang; Judith Trotman; Doreen Hallman; Ling Chen; John M Burke
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

5.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Brice; Y Bastion; E Lepage; N Brousse; C Haïoun; P Moreau; N Straetmans; H Tilly; I Tabah; P Solal-Céligny
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 6.  Marginal-Zone Lymphomas.

Authors:  Davide Rossi; Francesco Bertoni; Emanuele Zucca
Journal:  N Engl J Med       Date:  2022-02-10       Impact factor: 91.245

7.  Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials.

Authors:  Côme Bommier; Mathilde Ruggiu; Aymeric Monégier; Emanuele Zucca; Catherine Thieblemont; Jérôme Lambert
Journal:  Leuk Lymphoma       Date:  2022-02-24

Review 8.  Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.

Authors:  E Matutes; D Oscier; C Montalban; F Berger; E Callet-Bauchu; A Dogan; P Felman; V Franco; E Iannitto; M Mollejo; T Papadaki; E D Remstein; A Salar; F Solé; K Stamatopoulos; C Thieblemont; A Traverse-Glehen; A Wotherspoon; B Coiffier; M A Piris
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

9.  Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E Zucca; L Arcaini; C Buske; P W Johnson; M Ponzoni; M Raderer; U Ricardi; A Salar; K Stamatopoulos; C Thieblemont; A Wotherspoon; M Ladetto
Journal:  Ann Oncol       Date:  2019-12-04       Impact factor: 32.976

10.  Epidemiology of Marginal Zone Lymphoma.

Authors:  James R Cerhan; Thomas M Habermann
Journal:  Ann Lymphoma       Date:  2021-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.